🚀Enjoy a 7-Day Free Trial Until Jul 20, 2024!

AB

Abivax SAPAR Abivax Stock Report

Price

Market cap $B

Exchange

XPAR - Euronext Paris

FAIR VALUE

Is ABVX undervalued compared to its fair value?

The fair value of ABVX stock is hidden EUR. Relative to the market price of 12.54 EUR Abivax SA is hidden.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 24 full-time employees. The company went IP...[More about valuation]

Abivax SA Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.857 $B

Price:

12.54 EUR

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-1.447

FINANCIALS

Abivax SA financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.037 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.052 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.17 B
0.081 B

Financial Position Analysis

Assets

0.17 B
Current Assets
0.13 B
Total non-current assets
0.041 B

Total current liabilities
0.046 B
Total non-current liabilities
0.044 B

Cash Flow Statement

-0.032 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.028 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Abivax SA fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is ABVX attractive for investment based on fundamental analysis?

ABVX stock rating is hidden. Abivax SA is a hidden by Eyestock methodology.

Get ABVX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ABVX.PA analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ABVX.PA to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Abivax SA competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Abivax SA dividends

ABVX.PA dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ABVX.PA stock

About the company Abivax SA

Market cap $B

0.857

Dividend yield

Shares outstanding

42.318266 B

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 24 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

ABVX.PA profile

  • Ticker

    ABVX.PA

  • Country

    France

  • Exchange

    XPAR - Euronext Paris

  • Report currency

    EUR - Euro

  • IPO date

    26 June 2015

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    24

  • City

    Paris

  • Address

    5, rue de la Baume

  • Cusip

    F00182109